FrancophonIA/ELRC3.0 huggingface dataset:
English: Tygacil is an antibiotic of the glycylcycline group that works by stopping the growth of bacteria that cause infections.
Croatian: Tygacil je antibiotik iz glicilciklinske skupine koji djeluje tako da zaustavlja rast bakterija koje uzrokuju infekcije.
English: Patients who develop superinfections, in particular nosocomial pneumonia, appear to be associated with poorer outcomes.
Croatian: Čini se da su bolesnici koji razviju superinfekcije, osobito bolničku pneumoniju, povezani sa slabijim ishodima.
English: Tygacil is not to be used in children less than 8 years of age due to the lack of data on safety and efficacy in this age group and because it may induce permanent dental defects such as staining on the developing teeth.
Croatian: Tygacil se ne smije primjenjivati u djece mlađe od 8 godina zbog nedostatka podataka o sigurnosti i djelotvornosti u toj dobnoj skupini i jer može dovesti do trajnog oštećenja zuba, poput mrlja na zubima u razvoju.
English: Patients should be carefully monitored during therapy (see section 4.8).
Croatian: Bolesnike je za vrijeme terapije potrebno pažljivo nadzirati (vidjeti dio 4.8).
English: If you develop diarrhoea during or after your treatment, tell your doctor at once.
Croatian: Ukoliko dobijete proljev za vrijeme ili nakon liječenja, odmah o tome obavijestite Vašeg liječnika.
English: Population PK analysis of both studies identified body weight as a covariate of tigecycline clearance in children aged 8 years and older.
Croatian: Populacijska farmakokinetička analiza u oba ispitivanja utvrdila je da je tjelesna težina kovarijanta klirensa tigeciklina u djece u dobi od 8 godina i starijih.
English: In severe renal impairment, AUC was 30 % higher than in subjects with normal renal function (see section 4.2).
Croatian: U slučaju teškog oštećenja bubrega, AUC je bio 30% veći nego kod ispitanika s urednom funkcijom bubrega (vidjeti dio 4.2).
English: Tigecycline, a glycylcycline antibiotic, inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome.
Croatian: Tigeciklin, glicilciklinski antibiotik, inhibira translaciju proteina u bakterijama tako što se veže na ribosomsku podjedinicu 30S i blokira ulazak molekula amino-acil-tRNK na mjesto
English: Very limited safety data were available from two PK studies (see section 5.2).
Croatian: Dostupni su vrlo ograničeni podaci iz dva farmakokinetička ispitivanja (vidjeti dio 5.2).
English: Not known side effects are (frequency cannot be estimated from the available data):
Croatian: Nuspojave nepoznate učestalosti su (učestalost se ne može procijeniti iz dostupnih podataka):
English: • If you have or previously had any side effects due to antibiotics belonging to the tetracycline class (e.g., skin sensitization to sun light, staining on developing teeth, pancreas inflammation, and alteration of certain laboratory values aimed at measuring how well your blood clots).
Croatian: • Ukoliko ste prethodno imali bilo kakve nuspojave zbog antibiotika koji pripadaju skupini tetraciklina (npr. preosjetljivost kože na sunce, promjena boje zuba koji rastu, upala gušterače ili promjena nekih laboratorijskih nalaza kojima se određuje kako se zgrušava Vaša krv).
English: No dosage adjustment is warranted in patients with mild to moderate hepatic impairment (Child Pugh A and Child Pugh B).
Croatian: Nema potrebe za prilagodbom doze u bolesnika s blagim do umjereno teškim oštećenjem jetre (Child Pugh A i Child Pugh B).
English: Tigecycline is administered only by intravenous infusion over 30 to 60 minutes (see sections 4.4 and 6.6).
Croatian: Tigeciklin se primjenjuje isključivo kao intravenska infuzija u trajanju od 30 do 60 minuta (vidjeti dio 4.4 i 6.6).
English: In vitro studies using Caco-2 cells indicate that tigecycline does not inhibit digoxin flux, suggesting that tigecycline is not a P-glycoprotein (P-gp) inhibitor.
Croatian: In vitro ispitivanja koristeći Caco-2 stanice ukazuju da tigeciklin ne inhibira protok digoksina, sugerirajući da tigeciklin nije P-glikoproteinski (P-gp) inhibitor.
English: Decreased susceptibility in Acinetobacter baumannii has been attributed to the overexpression of the AdeABC efflux pump.
Croatian: Smanjena osjetljivost bakterije Acinetobacter baumannii pripisuje se pretjeranoj ekspresiji AdeABC efluks pumpe.
English: If you are allergic to tetracycline class antibiotics (e.g., minocycline, doxycycline, etc.), you may be allergic to tigecycline.
Croatian: Ukoliko ste alergični na tetraciklinsku skupinu antibiotika (npr. minociklin, doksiciklin, itd.), možete biti alergični i na tigeciklin.
English: Patients usually improve after tigecycline discontinuation.
Croatian: Bolesnici se obično oporave nakon prekida terapije tigeciklinom.
English: • Complicated intra-abdominal infections (cIAI).
Croatian: • Komplicirane intraabdominalne infekcije.
English: At 4 times the minimum inhibitory concentration (MIC), a 2-log reduction in colony counts was observed with tigecycline against Enterococcus spp., Staphylococcus aureus, and Escherichia coli.
Croatian: Pri koncentraciji 4 puta većoj od minimalne inhibicijske koncentracije (MIK) tigeciklina, opaženo je smanjenje za 2-log broja kolonija Enterococcus spp., Staphylococcus aureus i Escherichia coli.
English: Therefore, no breakpoint for susceptibility is given.
Croatian: Stoga nije moguće navesti graničnu vrijednost osjetljivosti.
English: • Low blood sugar
Croatian: • Niska razina šećera u krvi
English: For instructions on reconstitution & dilution of the medicinal product before administration, see section 6.6.
Croatian: Za upute o pripremi i razrjeđivanju lijeka prije primjene, vidjeti dio 6.6.
English: However, systemic clearance of tigecycline was reduced by 25 % and 55 % and the half-life of tigecycline was prolonged by 23 % and 43 % in patients with moderate or severe hepatic impairment (Child Pugh B and C), respectively (see section 4.2).
Croatian: Međutim, sistemski klirens tigeciklina bio je smanjen za 25%, odnosno 55%, a poluvijek tigeciklina bio je produžen za 23%, odnosno 43% u bolesnika sa srednje teškim, odnosno teškim oštećenjem jetre (Child Pugh B, odnosno C) (vidjeti dio 4.2).
English: No new or unexpected safety concerns were observed with tigecycline in these studies.
Croatian: U tim ispitivanjima nisu opažena nova ili neočekivana pitanja u vezi sa sigurnošću primjene tigeciklina.
English: The diagnosis of acute pancreatitis should be considered in patients taking tigecycline who develop clinical symptoms, signs, or laboratory abnormalities suggestive of acute pancreatitis.
Croatian: Potrebno je uzeti u obzir dijagnozu akutnog pankreatitisa u bolesnika koji primaju tigeciklin, a koji razvijaju kliničke simptome, znakove ili laboratorijske poremećaje koji upućuju na akutni pankreatitis.
English: The total clearance of tigecycline is 24 L/h after intravenous infusion.
Croatian: Ukupni klirens tigeciklina nakon intravenske infuzije iznosi 24 l/h.
English: Nausea and vomiting are very common adverse reactions in children and adolescents (see section 4.8).
Croatian: Mučnina i povraćanje vrlo su česte nuspojave u djece i odraslih (vidjeti dio 4.8).
English: In vitro studies in human liver microsomes indicate that tigecycline does not inhibit metabolism mediated by any of the following 6 cytochrome P450 (CYP) isoforms: 1A2, 2C8, 2C9, 2C19, 2D6, and 3A4 by competitive inhibition.
Croatian: In vitro ispitivanja s ljudskim jetrenim mikrosomima upućuju na to da tigeciklin ne inhibira metabolizam posredovan bilo kojim od slijedećih 6 izooblika citokroma P450 (CYP): 1A2, 2C8, 2C9, 2C19, 2D6 i 3A4 kompetitivnom inhibicijom.
English: Glucuronidation and renal excretion of unchanged tigecycline are secondary routes.
Croatian: Glukuronidacija i izlučivanje nepromijenjenog tigeciklina putem bubrega predstavljaju sekundarne puteve.
English: In an open-label, single ascending dose PK study, the safety of tigecycline was investigated in 25 children aged 8 to 16 years who recently recovered from infections.
Croatian: U otvorenom farmakokinetičkom ispitivanju s jednom postupno rastućom dozom sigurnost tigeciklina ispitivana je u 25 djece u dobi od 8 do 16 godina koja su se nedavno oporavila od infekcija.
English: Clinical experience in the use of tigecycline for the treatment of infections in paediatric patients aged 8 years and older is very limited (see sections 4.8 and 5.1).
Croatian: Kliničko iskustvo s upotrebom tigeciklina za liječenje infekcija u pedijatrijskih bolesnika u dobi od 8 godina i starijih vrlo je ograničeno (vidjeti dijelove 4.8 i 5.1).
English: Tigecycline is not extensively metabolised.
Croatian: Metabolizam tigeciklina nije opsežan.
English: If pancreatitis develops, treatment with tigecycline should be discontinued.
Croatian: Ako dođe do pankreatitisa, liječenje tigeciklinom mora se prekinuti.
English: Tigecycline is able to overcome the two major tetracycline resistance mechanisms, ribosomal protection and efflux.
Croatian: Tigeciklin može nadvladati dva glavna mehanizma rezistencije kod tetraciklina, ribosomsku zaštitu i efluks.
English: Race There were no differences in the clearance of tigecycline based on race.
Croatian: Rasa Nema razlika u klirensu tigeciklina koje se temelje na rasi.
English: Significant differences in sepsis/septic shock with tigecycline (2.2 %) vs comparators (1.1 %) were observed.
Croatian: Opažena je značajna razlika u sepsi/septičkom šoku s tigeciklinom (2,2 %) u odnosu na usporedne lijekove (1,1 %).
English: The single dose pharmacokinetic disposition of tigecycline was not altered in patients with renal insufficiency (creatinine clearance 30 ml/min, n=6).
Croatian: Farmakokinetička raspoloživost tigeciklina nakon jednokratnog doziranja nije bila promijenjena u bolesnika sa insuficijencijom bubrega (klirens kreatinina<30 ml/min, n=6).
English: • Low platelet levels in the blood(which may lead to an increased bleeding tendency and bruising/haematoma)
Croatian: • Niska razina krvnih pločica u krvi (koja može dovesti do povećane sklonosti krvarenju i modricama/hematomima)
English: In vitro, tigecycline is neither a competitive inhibitor nor an irreversible inhibitor of CYP450 enzymes (see section 5.2).
Croatian: Tigeciklin nije niti kompetitivni niti ireverzibilni inhibitor enzima CYP450 in vitro (vidjeti dio 5.2).
English: thrombocytopenia, increased international normalised ratio (INR)
Croatian: trombocitopenija, povećan međunarodni normalizirani omjer (INR)
English: Biliary excretion accounts for approximately 50 % of the total tigecycline excretion.
Croatian: Izlučivanje putem žuči odgovorno je za oko 50% ukupnog izlučivanja tigeciklina.
English: Inherently resistant organisms
Croatian: Prirođeno rezistentni organizmi
English: In general, tigecycline is considered bacteriostatic.
Croatian: Općenito se tigeciklin smatra bakteriostatskim antibiotikom.
English: For IV use only
Croatian: Samo za i.v. primjenu
English: Overall, the primary route of elimination for tigecycline is biliary excretion of unchanged tigecycline.
Croatian: Općenito, primarni put eliminacije tigeciklina jest izlučivanje nepromijenjenog tigeciklina putem žuči.
English: C-labelled tigecycline indicate that tigecycline is excreted readily via the milk of lactating rats.
Croatian: C-označen tigeciklin upućuju na to da se tigeciklin brzo izlučuje putem mlijeka štakorica tijekom laktacije.
English: Available pharmacodynamic/toxicological data in animals have shown excretion of tigecycline/metabolites in milk (see section 5.3).
Croatian: Dostupni farmakodinamički/toksikološki podaci u životinja pokazuju da se tigeciklin/metaboliti izlučuju u mlijeko (za detalje vidjeti 5.3).
English: Overgrowth of non-susceptible organisms, including fungi (see section 4.4).
Croatian: Prekomjerni rast neosjetljivih mikroorganizama, uključujući gljivice (vidjeti dio 4.4).
English: The recovery of the total radioactivity in faeces and urine following administration of
Croatian: Ukupna radioaktivnost koju je moguće pronaći u stolici i urinu nakon primjene
English: Once the powder has been made into a solution and diluted ready for use, it should be given to you immediately.
Croatian: Nakon što se prašak otopi i pripremljena otopina razrijedi, spremna je za primjenu i potrebno ju se odmah primijeniti.
English: Limited experience is also available in treating patients with concurrent bacteraemia (5.6 %).
Croatian: Također postoji ograničeno iskustvo u liječenju bolesnika s istovremenom bakterijemijom (5,6%).
English: Metabolism and nutrition disorders hypoglycaemia, hypoproteinaemia
Croatian: Poremećaji metabolizma i prehrane hipoglikemija, hipoproteinemija
English: Elderly No dosage adjustment is necessary in elderly patients (see section 5.2).
Croatian: Nije potrebna prilagodba doze u starijih bolesnika (vidjeti dio 5.2).
English: Tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections (see sections 4.4 and 5.1):
Croatian: Tygacil je indiciran u odraslih i u djece starije od osam godina za liječenje sljedećih infekcija (vidjeti dijelove 4.4 i 5.1):
English: The use of tigecycline may result in overgrowth of non-susceptible organisms, including fungi.
Croatian: Primjena tigeciklina može dovesti do pretjeranog rasta organizama koji nisu osjetljivi na ovaj lijek, uključujući gljivice.
English: There were a limited number of patients with severe underlying disease such as immunocompromised patients, patients with APACHE II scores  15 (3.3 %), or with surgically apparent multiple intra-abdominal abscesses (11.4 %).
Croatian: Uključen je ograničen broj bolesnika s teškom osnovnom bolešću, poput imunokompromitiranih bolesnika, bolesnika s APACHE II bodovima > 15 (3,3%) ili kirurški verificiranim višestrukim intraabdominalnim apscesima (11,4%).
English: Read the package leaflet before use for directions on reconstitution and dilution.
Croatian: Prije uporabe pročitati Uputu o lijeku za smjernice oko pripreme i razrjeđivanja.
English: In clinical trials, the most common medicinal product-related treatment emergent adverse reactions were reversible nausea (21 %) and vomiting (13 %), which usually occurred early (on treatment days 1-2) and were generally mild or moderate in severity.
Croatian: U kliničkim ispitivanjima najčešće nuspojave povezane s lijekom bile su mučnina (21%) i povraćanje (13%), koje su se obično javljale rano (1.- 2. dan liječenja) i općenito su bile blage do umjereno teške.
English: After reconstitution, 1 ml contains 10 mg of tigecycline.
Croatian: Nakon pripreme, 1 ml sadrži 10 mg tigeciklina.
English: Experience in the use of tigecycline for treatment of infections in patients with severe underlying diseases is limited.
Croatian: Iskustvo s primjenom tigeciklina u liječenju infekcija u bolesnika s teškim osnovnim bolestima je ograničeno.
English: Thus, 5 ml of reconstituted solution is equivalent to 50 mg of the active substance.
Croatian: Stoga 5 ml pripremljene otopine odgovara 50 mg djelatne tvari.
English: If this were the case, your doctor will monitor you closely.
Croatian: U tom će Vas slučaju liječnik češće kontrolirati.
English: • Complicated infection of the skin and soft tissues (the tissue below the skin), excluding diabetic foot infections.
Croatian: • Kompliciranu infekciju kože i mekih tkiva (tkiva ispod kože), ne uključujući infekcije dijabetičkog stopala
English: • Increases in liver enzymes, hyperbilirubinaemia (excess of bile pigment in the blood)
Croatian: • Porast jetrenih enzima, hiperbilirubinemija (višak žučnog pigmenta u krvi)
English: Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:
Croatian: Europska komisija za ispitivanje osjetljivosti na antimikrobne lijekove (EUCAST, European Committee on Antimicrobial Susceptibility Testing) utvrdila je sljedeće granične vrijednosti minimalne inhibicijske koncentracije (MIK):
English: SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
Croatian: POSEBNE MJERE ZA ZBRINJAVANJE E NEISKORIŠTENOG LIJEKA ILI OTPADNIH MATERIJALA KOJI POTJEČU
English: The steady-state AUC0-12h was 2349±850 ng•h/ml.
Croatian: AUC0-12h u stanju dinamičke ravnoteže iznosio je 2349±850 ng•h/ml.
English: If you are concerned that you may have been given too much Tygacil, talk to your doctor or nurse immediately.
Croatian: Ako Vas brine to da ste možda primili previše Tygacila, odmah razgovarajte s Vašim liječnikom ili medicinskom sestrom.
English: C-labelled material recovered in urine and faeces, but a glucuronide, an N-acetyl metabolite and a tigecycline epimer were also present.
Croatian: C-označenog materijala koji se mogao naći u urinu i stolici, ali bili su prisutni i glukuronid, N-acetilski metabolit, kao i epimer tigeciklina.
English: In clinical trials in cIAI, the most common type of infection in tigecycline-treated patients was complicated appendicitis (50.3 %), followed by other diagnoses less commonly reported such as complicated cholecystitis (9.6 %), perforation of intestine (9.6 %), intra-abdominal abscess (8.7 %), gastric or duodenal ulcer perforation (8.3 %), peritonitis (6.2 %) and complicated diverticulitis (6.0 %).
Croatian: U kliničkim ispitivanjima s cIAI-ovima (engl. complicated intra-abdominal infections), najčešći oblik infekcije u bolesnika koji su liječeni tigeciklinom bio je komplicirani apendicitis (50,3%), a potom slijede ostale rjeđe prijavljene dijagnoze poput kompliciranog kolecistitisa (9,6%), perforacija crijeva (9,6%), intraabdominalnog apscesa (8,7%), perforacije želučanog ili duodenalnog ulkusa (8,3%), peritonitis (6,2%) i komplicirani divertikulitis (6,0%).
English: Children and adolescents (8 to 17 years of age) Tigecycline is only to be used to treat patients aged 8 years and older after consultation with a physician with appropriate experience in the management of infectious diseases.
Croatian: Tigeciklin se smije upotrebljavati za liječenje bolesnika u dobi od 8 godina i starijih samo nakon savjetovanja s liječnikom koji ima odgovarajuće iskustvo u liječenju infektivnih bolesti.
English: The reconstituted solution should be yellow to orange in colour; if not, the solution should be discarded.
Croatian: Pripremljena otopina trebala bi biti žute do narančaste boje; ukoliko to nije slučaj, otopinu treba odbaciti.
English: In in vitro studies, no antagonism has been observed between tigecycline and other commonly used antibiotic classes.
Croatian: U in vitro ispitivanjima nije opažen antagonizam između tigeciklina i ostalih često primjenjivanih skupina antibiotika.
English: Do not take any diarrhoea medicine without first checking with your doctor.
Croatian: Nemojte uzimati lijekove protiv proljeva prije nego što se posavjetujete s Vašim liječnikom.
English: Results of animal studies indicate that tigecycline crosses the placenta and is found in foetal tissues.
Croatian: Rezultati ispitivanja na životinjama upućuju na to da tigeciklin prolazi kroz posteljicu i može se naći u fetalnim tkivima.
English: The following active substances should not be administered simultaneously through the same Y-site as tigecycline: Amphotericin B, amphotericin B lipid complex, diazepam, esomeprazole, omeprazole and intravenous solutions that could result in an increase of pH above 7.
Croatian: Slijedeće djelatne tvari ne smiju se primjenjivati kroz istu infuzijsku Y-liniju istovremeno s tigeciklinom: amfotericin B, amfotericin B lipidni kompleks, diazepam, esomeprazol, omeprazol i intravenske otopine koje mogu povisiti pH iznad 7.
English: Limited experience is also available in treating patients with concurrent bacteraemia (3.4 %).
Croatian: Također postoji samo ograničeno iskustvo u liječenju bolesnika s istovremenom bakterijemijom (3,4%).
English: Patients with severe underlying disease, such as those that were immunocompromised, patients with decubitus ulcer infections, or patients that had infections requiring longer than 14 days of treatment (for example, necrotizing fasciitis), were not enrolled.
Croatian: U ispitivanja nisu bili uključeni bolesnici s teškom osnovnom bolešću, poput onih koji su imunokompromitirani, zatim bolesnici s infekcijama dekubitalnog ulkusa ili bolesnici s infekcijom koja je zahtijevala više od 14 dana liječenja (primjerice, nekrotizirajući fasciitis).
English: Based on an in vitro study tigecycline is a P-gp substrate.
Croatian: Na temelju in vitro studija tigeciklin je P-gp supstrat.
English: A dosing regimen of 1.2 mg/kg of tigecycline every 12 hours (to a maximum dose of 50 mg every 12 hours) for children aged 8 to <12 years and of 50 mg every 12 hours for adolescents aged 12 to <18 years would likely result in exposures comparable to those observed in adults treated with the approved dosing regimen.
Croatian: Režim doziranja od 1,2 mg/kg tigeciklina svakih 12 sati (do maksimalne doze od 50 mg svakih 12 sati) za djecu u dobi od 8 do <12 i od 50 mg svakih 12 sati za adolescente u dobi od 12 do <18 najvjerojatnije će rezultirati izloženostima usporedivim s uočenima u odraslih liječenih odobrenim režimom doza.
English: Glycylcycline class antibiotics are structurally similar to tetracycline class antibiotics.
Croatian: Glicilciklinski razred antibiotika je strukturno sličan tetraciklinskom razredu antibiotika.
English: Tigecycline should be preferably administered over a 60-minute length of infusion in paediatric patients.
Croatian: Tigeciklin treba po mogućnosti primjenjivati u infuziji trajanja 60 minuta u pedijatrijskih bolesnika.
English: However, since tigecycline may prolong both prothrombin time (PT) and activated partial thromboplastin time (aPTT), the relevant coagulation tests should be closely monitored when tigecycline is co-administered with anticoagulants (see section 4.4).
Croatian: Međutim, budući da tigeciklin može produžiti kako protrombinsko vrijeme (PV), tako i aktivirano parcijalno tromboplastinsko vrijeme (APTV), potrebna je česta kontrola relevantnih koagulacijskih testova u slučaju istovremene primjene tigeciklina i antikoagulansa (vidjeti dio 4.4).
English: What Tygacil looks like and contents of the pack Tygacil is supplied as a powder for solution for infusion in a vial and looks like an orange powder or cake before it is diluted.
Croatian: Tygacil je dostupan kao prašak za otopinu za infuziju u bočici i prije razrjeđivanja izgleda kao narančasti prašak ili kolačić.
English: When administered through a Y-site, compatibility of tigecycline diluted in sodium chloride 0.9 % for injection is demonstrated with the following medicinal products or diluents: amikacin, dobutamine, dopamine HCl, gentamicin, haloperidol, Lactated Ringer's, lidocaine HCl, metoclopramide, morphine, norepinephrine, piperacillin/tazobactam (EDTA formulation), potassium chloride, propofol, ranitidine HCl, theophylline, and tobramycin.
Croatian: U slučaju primjene kroz Y-liniju, dokazana je kompatibilnost tigeciklina razrijeđenog u 0,9%-tnoj otopini natrijevog klorida sa slijedećim lijekovima ili otapalima: amikacin, dobutamin, dopaminklorid, gentamicin, haloperidol, Ringerova otopina s laktatom, lidokainklorid, metoklopramid, morfin, norepinefrin, piperacilin/tazobaktam (EDTA formulacija), kalijev klorid, propofol, ranitidinklorid, teofilin i tobramicin.
English: Therefore, clearance of tigecycline is not expected to be affected by active substances that inhibit or induce the activity of the CYP450 isoforms.
Croatian: Stoga se ne očekuje značajniji utjecaj djelatnih tvari koje inhibiraju ili induciraju aktivnost izoenzima CYP450 na klirens tigeciklina.
English: Digoxin did not affect the pharmacokinetic profile of tigecycline.
Croatian: Digoksin nije utjecao na farmakokinetički profil tigeciklina.
English: In clinical pharmacology studies using the therapeutic dosage regimen of 100 mg followed by 50 mg q12h, serum tigecycline steady-state Cmax was 866±233 ng/ml for 30-minute infusions and 634±97 ng/ml for 60-minute infusions.
Croatian: U kliničkim farmakološkim ispitivanjima u kojima je primjenjivana terapijska shema doziranja od 100 mg, nakon čega slijedi 50 mg svakih 12 sati, Cmax serumskog tigeciklina u stanju dinamičke ravnoteže iznosila je 866±233 ng/ml za 30-minutnu infuziju, odnosno 634±97 ng/ml za 60-minutne infuzije.